Robert A. Gabbay, M.D., Ph.D., goes over Shared Medical Appointments (SMAs) and why they can make such a difference for practitioners, including the extra benefit of a peer group supporting each other. Other videos with Dr. Robert A. Gabbay: Robert A. Gabbay, MD, PhD, Introduction Q1: The ACA’s Effects on …

Robert A. Gabbay, M.D., Ph.D., discusses the future of medicine, letting us know that he believes that, with some rocky periods immediately ahead, in general, he believes that there will be more focus on quality not quantity in medical care, fewer procedures and more prevention, primary care will expand and …

Robert A. Gabbay, M.D., Ph.D., gives us a few ideas on how you can motivate your patients, including motivational interviewing. He points out that more than any other disease, diabetes management is reliant on the patient’s self-care so motivating patients is critical….

Robert A. Gabbay, M.D., Ph.D., talks about the newest technological tools available to both patients and practitioners, as well as the potential for much better coordination and care utilizing what we are now learning from the large amounts of patient data being gathered. This new wealth of information will enable …

Robert A. Gabbay, M.D., Ph.D., talks about the challenges diabetes professionals will be facing in the coming years including helping patients to take advantage of tools that are already available to them. But he points out that the biggest challenge will continue to be figuring out how to guide people …

Robert A. Gabbay, M.D., Ph.D., talks about the huge challenges posed by the diabetes epidemic and some of the innovative solutions that public health officials are using to fight the disease’s spread in our society. He also notes that the food and agriculture industries are often promoting some of the …

Robert A. Gabbay, M.D., Ph.D., talks about how medical schools are adjusting their curriculums to cover topics important in today’s medical system including more focus on nutrition science and preparing younger physicians to work within a team framework. He notes that many of these shifts in the system will work …

Last Friday, the FDA approved the SGLT2 inhibitor dapaglifozin. This is the second drug in the SGLT2-I class and so now the battle of superiority, dapagliflozin versus canagliflozin, begins. There will also be extra pressure from the DPP4-I companies to downplay the value of this drug class. This week, in …

Ramzi Ajjan, MRCP, Med Sci, PhD   Acute confusion in an 82-year-old with known type 2 diabetes Brian, an 82-year-old gentleman with known type 2 diabetes, is brought to A&E with general deterioration and acute confusion. What differential diagnoses would you consider and what would you do?…

I am at the annual Consumer Electronics Show in Las Vegas this week and it is easy to see how technology is moving into the healthcare segment. Three years ago, less than 2% of the booths were dedicated to health and wellness — this year, a full 30% of them …